Delayed cardiomyopathy in dystrophin deficient mdx mice relies on intrinsic glutathione resource

American Journal of Pathology

Volumn 177, Issue 3, 2010, Pages 1356-1364

  Khouzami, Lara ^a,b   Bourin, Marie Claude ^a,b   Christov, Christo ^a,b,c   Damy, Thibaud ^a,b   Escoubet, Brigitte ^d   Caramelle, Philippe ^a,b   Perier, Magali ^a,b   Wahbi, Karim ^e,f   Meune, Christophe ^d   Pavoine, Catherine ^a,b   Pecker, Françoise ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c Plate Forme d'Imagerie Cellulaire et Tissulaire   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e BICHAT HOSPITAL   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DYSTROGLYCAN; BUTHIONINE SULFOXIMINE; DYSTROPHIN; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CASE REPORT; DIASTOLIC DYSFUNCTION; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICROANGIOPATHY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

EID: 77956501824     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090479     Document Type: Article

References (62)

1. Hoffman EP, Fischbeck KH, Brown RH, Johnson M, Medori R, Loike JD, Harris JB, Waterston R, Brooke M, Specht L, Kupsky W, Chamberlain J, Caskey Y, Shapiro F, Kunkel LM: Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 1988, 318:1363-1368
2. Chapman VM, Miller DR, Armstrong D, Caskey CT: Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci USA 1989, 86:1292-1296
3. Allamand V, Campbell KP: Animal models for muscular dystrophy: valuable tools for the development of therapies. Hum Mol Genet 2000, 9:2459-2467
4. Ferrari G, Stornaiuolo A, Mavilio F: Failure to correct murine muscular dystrophy. Nature 2001, 411:1014-1015 (Pubitemid 32612316)
5. Connolly AM, Keeling RM, Mehta S, Pestronk A, Sanes JR: Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord 2001, 11:703-712 (Pubitemid 32930018)
6. Chretien F, Dreyfus PA, Christov C, Caramelle P, Lagrange JL, Chazaud B, Gherardi RK: In vivo fusion of circulating fluorescent cells with dystrophin-deficient myofibers results in extensive sarcoplasmic fluorescence expression but limited dystrophin sarcolemmal expression. Am J Pathol 2005, 166:1741-1748
7. Duan D: Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet 2006, 15 Spec No 2:R253-R261
8. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL: Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993, 90:3710-3714
9. Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, Des Rosiers C, Petrof BJ: Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J 2001, 15:1655-1657
10. Townsend D, Yasuda S, Metzger J: Cardiomyopathy of Duchenne muscular dystrophy: pathogenesis and prospect of membrane sealants as a new therapeutic approach. Expert Rev Cardiovasc Ther 2007, 5:99-109
11. Rando TA, Disatnik MH, Yu Y, Franco A: Muscle cells from mdx mice have an increased susceptibility to oxidative stress. Neuromuscul Disord 1998, 8:14-21 (Pubitemid 28174930)
12. Messina S, Altavilla D, Aguennouz M, Seminara P, Minutoli L, Monici MC, Bitto A, Mazzeo A, Marini H, Squadrito F, Vita G: Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 2006, 168:918-926 (Pubitemid 43327744)
13. Tidball JG, Wehling-Henricks M: The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol 2007, 102: 1677-1686 (Pubitemid 46571068)
14. Rando TA: Role of nitric oxide in the pathogenesis of muscular dystrophies: a "two hit" hypothesis of the cause of muscle necrosis. Microsc Res Tech 2001, 55:223-235
15. Dudley RW, Danialou G, Govindaraju K, Lands L, Eidelman DE, Petrof BJ: Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stresses. Am J Pathol 2006, 168:1276-1287; quiz 1404-1275
16. Buetler TM, Renard M, Offord EA, Schneider H, Ruegg UT: Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J Clin Nutr 2002, 75:749-753 (Pubitemid 34250689)
17. Whitehead NP, Pham C, Gervasio OL, Allen DG: N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J Physiol 2008, 586:2003-2014 (Pubitemid 351997524)
18. Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA: Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem 1998, 273:11313-11320 (Pubitemid 28204985)
19. Pavoine C, Pecker F: Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 2009, 82:175-183
20. Bourraindeloup M, Adamy C, Candiani G, Cailleret M, Bourin MC, Badoual T, Su JB, Adubeiro S, Roudot-Thoraval F, Dubois-Rande JL, Hittinger L, Pecker F: N-acetylcysteine treatment normalizes serum tumor necrosis factor-alpha level and hinders the progression of cardiac injury in hypertensive rats. Circulation 2004, 110:2003-2009
21. Adamy C, Mulder P, Khouzami L, Andrieu-Abadie N, Defer N, Candiani G, Pavoine C, Caramelle P, Souktani R, Le Corvoisier P, Perier M, Kirsch M, Damy T, Berdeaux A, Levade T, Thuillez C, Hittinger L, Pecker F: Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. J Mol Cell Cardiol 2007, 43:344-353 (Pubitemid 47301939)
22. Damy T, Kirsch M, Khouzami L, Caramelle P, Le Corvoisier P, Roudot- Thoraval F, Dubois-Rande JL, Hittinger L, Pavoine C, Pecker F: Glutathione deficiency in cardiac patients is related to the functional status and structural cardiac abnormalities. PLoS ONE 2009, 4:e4871
23. Haddad JJ, Harb HL: L-gamma-Glutamyl-L-cysteinyl-glycine (glutathione; GSH) and GSH-related enzymes in the regulation of pro- and anti-inflammatory cytokines: a signaling transcriptional scenario for redox (y) immunologic sensor (s) ? Mol Immunol 2005, 42:987-1014
24. Townsend DM, Tew KD, Tapiero H: The importance of glutathione in human disease. Biomed Pharmacother 2003, 57:145-155
25. Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI: The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem 2007, 113:234-258
26. Degl'Innocenti D, Rosati F, Iantomasi T, Vincenzini MT, Ramponi G: GSH system in relation to redox state in dystrophic skin fibroblasts. Biochimie 1999, 81:1025-1029
27. Dudley RW, Khairallah M, Mohammed S, Lands L, Des Rosiers C, Petrof BJ: Dynamic responses of the glutathione system to acute oxidative stress in dystrophic mouse (mdx) muscles. Am J Physiol Regul Integr Comp Physiol 2006, 291:R704-R710
28. Finsterer J, Stollberger C: The heart in human dystrophinopathies. Cardiology 2003, 99:1-19
29. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS: Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 2004, 14:491-496
30. Forgione MA, Cap A, Liao R, Moldovan NI, Eberhardt RT, Lim CC, Jones J, Goldschmidt-Clermont PJ, Loscalzo J: Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation 2002, 106:1154-1158 (Pubitemid 34970859)
31. Yucel D, Aydogdu S, Cehreli S, Saydam G, Canatan H, Senes M, Cigdem Topkaya B, Nebioglu S: Increased oxidative stress in dilated cardiomyopathic heart failure. Clin Chem 1998, 44:148-154 (Pubitemid 28042480)
32. Watanabe T, Sagisaka H, Arakawa S, Shibaya Y, Watanabe M, Igarashi I, Tanaka K, Totsuka S, Takasaki W, Manabe S: A novel model of continuous depletion of glutathione in mice treated with L-buthionine (S,R)-sulfoximine. J Toxicol Sci 2003, 28:455-469 (Pubitemid 38133224)
33. Pastoret C, Sebille A: Age-related differences in regeneration of dystrophic (mdx) and normal muscle in the mouse. Muscle Nerve 1995, 18:1147-1154
34. McGeachie JK, Grounds MD, Partridge TA, Morgan JE: Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies. J Neurol Sci 1993, 119:169-179
35. Nigro G, Comi LI, Palladino A, Petretta VR, Politano L: Cardiomyopathies: diagnosis of types and stages. Acta Myol 2004, 23:97-102
36. Crilley JG, Boehm EA, Rajagopalan B, Blamire AM, Styles P, Muntoni F, Hilton-Jones D, Clarke K: Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy. J Am Coll Cardiol 2000, 36:1953-1958
37. Danko I, Chapman V, Wolff JA: The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. Pediatr Res 1992, 32:128-131
38. Collins KA, Korcarz CE, Shroff SG, Bednarz JE, Fentzke RC, Lin H, Leiden JM, Lang RM: Accuracy of echocardiographic estimates of left ventricular mass in mice. Am J Physiol Heart Circ Physiol 2001, 280:H1954-H1962
39. Scorsin M, Hagege A, Vilquin JT, Fiszman M, Marotte F, Samuel JL, Rappaport L, Schwartz K, Menasche P: Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg 2000, 119:1169-1175
40. Tietze F: Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969, 27:502-522
41. Rahman I, Kode A, Biswas SK: Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 2006, 1:3159-3165
42. Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P, Manin S, Deveaux V, Bourin MC, Zimmer A, Lotersztajn S, Pecker F, Pavoine C: The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy, FASEB J 2009, 23:2120-2130
43. Ponchel F, Toomes C, Bransfield K, Leong FT, Douglas SH, Field SL, Bell SM, Combaret V, Puisieux A, Mighell AJ, Robinson PA, Inglehearn CF, Isaacs JD, Markham AF: Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 2003, 3:18
44. Hunter MI, Mohamed JB: Plasma antioxidants and lipid peroxidation products in Duchenne muscular dystrophy. Clin Chim Acta 1986, 155:123-131
45. Austin L, de Niese M, McGregor A, Arthur H, Gurusinghe A, Gould MK: Potential oxyradical damage and energy status in individual muscle fibres from degenerating muscle diseases. Neuromuscul Disord 1992, 2:27-33
46. Rodriguez MC, Tarnopolsky MA: Patients with dystrophinopathy show evidence of increased oxidative stress. Free Radic Biol Med 2003, 34:1217-1220
47. Williams IA, Allen DG: The role of reactive oxygen species in the hearts of dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 2007, 293:H1969-H1977
48. Kar NC, Pearson CM: Catalase, superoxide dismutase, glutathione reductase and thiobarbituric acid-reactive products in normal and dystrophic human muscle. Clin Chim Acta 1979, 94:277-280
49. Pastoret C, Sebille A: mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 1995, 129:97-105
50. Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA: Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol 2001, 535:591-600
51. Lowe DA, Williams BO, Thomas DD, Grange RW: Molecular and cellular contractile dysfunction of dystrophic muscle from young mice. Muscle Nerve 2006, 34:92-100
52. Wehling-Henricks M, Jordan MC, Roos KP, Deng B, Tidball JG: Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet 2005, 14:1921-1933
53. Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, Metzger JM: Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 2007, 15:1086-1092
54. De Lorenzo F, Xiao H, Mukherjee M, Harcup J, Suleiman S, Kadziola Z, Kakkar VV: Chronic fatigue syndrome: physical and cardiovascular deconditioning. QJM 1998, 91:475-481 (Pubitemid 28325346)
55. Miwa K, Fujita M: Small heart syndrome in patients with chronic fatigue syndrome. Clin Cardiol 2008, 31:328-333
56. Bia BL, Cassidy PJ, Young ME, Rafael JA, Leighton B, Davies KE, Radda GK, Clarke K: Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 1999, 31:1857-1862
57. Nigro G, Comi LI, Politano L, Bain RJ: The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990, 26:271-277
58. Chaiswing L, Cole MP, St Clair DK, Ittarat W, Szweda LI, Oberley TD: Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol Pathol 2004, 32:536-547
59. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, Yodoi J: Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 2002, 106:1403-1409
60. Andreetta F, Bernasconi P, Baggi F, Ferro P, Oliva L, Arnoldi E, Cornelio F, Mantegazza R, Confalonieri P: Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J Neuroimmunol 2006, 175:77-86
61. Behr J, Demedts M, Buhl R, Costabel U, Dekhuijzen RP, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Lankhorst I, Sardina M, Boissard G: Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial. Respir Res 2009, 10:101
62. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, Macnee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2229-2242